PharmaCyte Biotech Inc Cash Flow Quality Index
PharmaCyte Biotech Inc cash flow quality index. PharmaCyte Biotech Inc (PMCB) has a Cash Flow Quality Index of -1.05x as of January 2026. Operating cash flow of $-786.85K is below net income of $746.86K, suggesting accrual-heavy earnings not yet converted to cash. See financial flexibility index of PharmaCyte Biotech Inc to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of PharmaCyte Biotech Inc (2024–2025)
Cash flow quality index of PharmaCyte Biotech Inc from 2024 to 2025. Historical Cash Flow Quality Index for PharmaCyte Biotech Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore cash flow to debt ratio of PharmaCyte Biotech Inc to assess how comfortably operating cash covers total debt obligations.
PharmaCyte Biotech Inc Cash Flow Quality Index by Year (2024–2025)
PharmaCyte Biotech Inc cash flow quality index by year from 2024 to 2025. Year-by-year earnings quality comparison for PharmaCyte Biotech Inc. For the full cash flow conversion analysis, see how efficiently does PharmaCyte Biotech Inc generate cash.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | $-2.98 Million | $30.66 Million | ▲ +98.5% |
| 2024 | -6.45x | $-2.15 Million | $333.76K | — |